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Abstract
This paper describes extending plug-based microfluidics to handling complex biological fluids such
as blood, solving the problem of injecting additional reagents into plugs, and applying this system
to measuring of clotting time in small volumes of whole blood and plasma. Plugs are droplets
transported through microchannels by fluorocarbon fluids. A plug-based microfluidic system was
developed to titrate an anticoagulant (argatroban) into blood samples and to measure the clotting
time using the activated partial thromboplastin time (APTT) test. To carry out these experiments, the
following techniques were developed for a plug-based system: (i) using Teflon AF coating on the
microchannel wall to enable formation of plugs containing blood and transport of the solid fibrin
clots within plugs, (ii) using a hydrophilic glass capillary to enable reliable merging of a reagent from
an aqueous stream into plugs, (iii) using bright-field microscopy to detect the formation of a fibrin
clot within plugs and using fluorescent microscopy to detect the production of thrombin using a
fluorogenic substrate, and (iv) titration of argatroban (0–1.5 μg/mL) into plugs and measurement of
the resulting APTTs at room temperature (23 °C) and physiological temperature (37 °C). APTT
measurements were conducted with normal pooled plasma (platelet-poor plasma) and with donor’s
blood samples (both whole blood and platelet-rich plasma). APTT values and APTT ratios measured
by the plug-based microfluidic device were compared to the results from a clinical laboratory at 37
°C. APTT obtained from the on-chip assay were about double those from the clinical laboratory but
the APTT ratios from these two methods agreed well with each other.
This paper describes the development of a plug-based microfluidic system capable of titrating
an anticoagulant drug, argatroban, into human blood samples and measuring the resulting
clotting times. A method for injecting reagents into flowing plugs is also described.
Determining the correct dose of an anticoagulant drug is important, as too little of the drug will
not be effective while too much of the drug can result in uncontrolled bleeding. Argatroban
directly inhibits the active site of thrombin, an essential enzyme in the coagulation cascade.1
This inhibitor is an effective treatment for heparin-induced thrombocytopenia (HIT).2 Heparin
is a common anticoagulant used to treat thromboembolic diseases and to prevent thrombosis
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in vascular procedures and after certain surgeries. However, with prolonged use of heparin,
~50% of patients develop antibodies to heparin3 and ~5% develop HIT,1 a heparin-induced
immune response that results in an uncontrolled hypercoagulable state, which can lead to deep
vein thrombosis, multiple organ failure, amputation, and even death. In medical procedures,
argatroban can be used as heparin substitute in patients in whom heparin use is contraindicated.
Currently, the appropriate dose of argatroban is determined for each patient individually. First,
the baseline clotting time is measured of the patient’s blood sample. Then, a protocol is
followed where a certain amount of argatroban is administered intravenously, a blood sample
is drawn after 2 h (the steady-state levels of drug and anticoagulant activity are reached within
1–3 h), and the clotting time is measured.4 This clotting time is determined using the activated
partial thromboplastin time (APTT) test, which typically takes another 1–2 h for a central
clinical laboratory to process.5 After this test, the administered dose of argatroban is adjusted
accordingly and this protocol is repeated until the clotting time is 1.5–3.0 times the baseline
clotting time. The entire process of determining the correct dose of the anticoagulant may take
half a day while causing significant patient discomfort from multiple needle sticks to obtain
blood samples. Therefore, an appropriate dose for a patient can be determined more efficiently
and conveniently if there is a rapid and reliable in vitro assay that performs these titrations
using a minimal amount of the patient’s blood prior to argatroban administration. Ideally, the
dose is predetermined and aPTT is measured at most once at steady state for confirmation after
administration.
Microfluidic systems have been applied for a range of biological assays6–11 that benefit from
aspects of miniaturization, such as smaller sample requirement, shorter analysis time, and
higher levels of automation and high-throughput. These lab-on-a-chip technologies have been
implemented with blood samples12 for rapid analyte detection,13–16 on-chip cell separation,
16–20 micro-thrombus formation,21 platelet activation,22 plasma separation from whole
blood,23 blood rheology,24,25 and red blood cell analysis.26–29 In addition, commercially
available point-of-care devices have been developed, where a droplet of blood (~15–50 μL) is
drawn into a microcapillary by capillary action and formation of the clot is detected by various
mechanical and optical methods.5, 30–37 There are various methods for detection of the fibrin
clot within these devices, such as the use of magnetic particles, LED optical detectors, a plunger
assembly, an amperometer, a laser beam to detect transmittance, or an ultrasonic probe.32 A
wide range of point-of-care devices are commercially available and have been used when rapid
turnaround time (minutes versus ~1–2 h for results from a central clinical laboratory) is
essential, such as for cardiac surgery.5,32 Results from these point-of-care devices and from
clinical laboratories have been determined to be comparable,33–35 and devices are even
available for home use.30,36
There are four difficulties when using single-phase flow in microfluidics to titrate drugs into
blood samples while measuring the resulting clotting times. First, pressure-driven laminar flow
results in dispersion of reagents along the channel. Second, laminar flow also results in slow
mixing. Third, due to the high surface area-to-volume ratio in microfluidic devices, surface
adsorption must be controlled to ensure correct analysis. Fourth, the formation of aggregates
and clots may result in contamination or blockage of the microchannels. Commercially
available micro-capillary devices use single-phase flow and are for single use only. However,
the titration of reagents using single-phase flow can be achieved by using multichannel devices
where each channel contains a different concentration of the reagent.
Multiphase flow in microfluidics systems can address the problems that arise in single-phase
flow. By forming air–liquid segments within capillaries,38–41 segmented flow injection
analysis has been used for automated analysis of samples, including blood.42,43 Discrete air
bubbles were used to separate aqueous samples within the capillaries.
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We emphasize that plug-based microfluidics (liquid–liquid segmented flow) differs
fundamentally from air–liquid segmented flows. In air–liquid segmented flow, dispersion is
reduced with the use of air bubbles (compared to flow without bubbles) but it is not eliminated.
Also, the aqueous sample is in direct contact with the capillary, which results in cross-
contamination of samples. Therefore, the surface chemistry of the capillary must be treated to
inhibit adsorption of the fibrin clot. On the scale of nanoliter volumes, surface chemistry
becomes especially important, and generally, there are two solutions to address this problem.
The surface can be treated to inhibit any adsorption of the sample, or droplets can be used to
encapsulate the sample so that the sample is not in contact with the surface. In a plug-based
microfluidic system, flows of immiscible aqueous and fluorous liquids are used to form plugs
(nanoliter-sized droplets) within the microchannels and result in four differences between air–
liquid versus liquid–liquid segmented flows. First, dispersion is eliminated by encapsulating
the aqueous reagents within the plugs, and cross-contamination between plugs is also
eliminated.44,45 Second, the products from the reaction do not adsorb to and contaminate the
walls of the microchannel. The reaction occurs within the dispersed phase (aqueous) and only
the continuous phase (fluorous) is in contact with the surface of the microchannel. Therefore,
the products of the reaction remain contained within the plugs, including even solid products
that otherwise would adhere to the walls.46 Third, mixing within plugs can be very rapid by
using chaotic advection induced by winding channels.45, 47–49 These winding channel
designs have also been incorporated for air–liquid segmented flow systems to achieve rapid
mixing.50 Fourth, the surface chemistry at the aqueous–fluorous interface of plugs can be
controlled using fluorous-soluble surfactants that do not appear to interfere with the proteins
in the aqueous phase.51 Plug-based systems can perform the same functions as air–liquid
segmented flow systems, but plugs also maintain the four advantages that was described above.
Plug-based microfluidic systems provide chemical microreactors with well-controlled mixing,
47,52 biocompatibility at the aqueous–fluorous interface,51 capability of titrating reagents,
53,54 and merging of reagents.45,46,55 Under a steady flow of plugs traveling through the
microchannel, each position along the microchannel corresponds to a specific residence time.
45,47,54 One can also follow a reaction over time by following plugs moving along the
microchannel.
Droplet-based microfluidic systems relying on liquid–liquid segmented flow have been
developed45,56–65 and used for applications such as PCR amplification,66,67 measurement
of enzyme kinetics,51,54 cell and protein encapsulation,68–70 growth of cell cultures,71,72
and formation of particles.46,52,73–77 Droplet-based microfluidic systems relying on gas–
liquid segmented flow have also been developed50,78 and used for analyte detection79 and
DNA analysis.80 Electrowetting has been used for dispensing, transporting, and mixing within
droplets81–84 and has been used for applications such as droplet formation containing various
human fluids,85 glucose detection,86 peptide analysis using mass spectrometry,87,88 and
synthesis of polymer particles.89
In this paper, we determined the APTT using a plug-based microfluidic platform with and
without titrating argatroban. When coagulation is initiated via the intrinsic pathway, the APTT
is the elapsed time between the addition of CaCl2 and the detection of a fibrin clot in the blood
sample.1 To measure the APTT on-chip, we further developed the plug-based microfluidic
technology to achieve the following: (i) form plugs containing blood and transport the solid
clots within the plugs through microchannels without contaminating the walls; (ii) control the
merging of a reagent into a plug, which is important for multistep assays such as the APTT
test; (iii) detect clots within plugs containing whole blood or plasma; and (iv) titrate argatroban
into plugs and measure the resulting APTTs at 23 and 37 °C.
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EXPERIMENTAL SECTION
Reagents and Solutions
All aqueous solutions were prepared in 18-MΩ deionized water (Millipore, Billerica, MA).
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.
A fluorogenic substrate for human α-thrombin, tert-butyloxycarbonyl-β-benzyl-l-aspartyl-l-
prolyl-l-arginine-4-methyl-coumaryl-7-amide (λex = 365 nm, λem = 440 nm), was purchased
from Peptide Institute, Inc. (Osaka, Japan). For this substrate, kinetic parameters at 37 °C were
kcat = 160 s−1, KM = 11 μM in buffer solution of 50 mM Tris-HCl, pH 8.0, with 0.15 M NaCl,
1 mM CaCl2, and 1 mg/mL BSA.90 The APTT reagent, Sigma Diagnostics Alexin, was
obtained from Trinity Biotech (Wicklow, Ireland). Argatroban (stock concentration of 100 mg/
mL) was obtained from GlaxoSmithKline (Philadelphia, PA). This stock was diluted to 1 mg/
mL with 150 mM NaCl, 20 mM Tris, pH 7.8, prior to the experiment. 1H,1H,2H,2H-
perfluoro-1-octanol (PFO, 98%) was obtained from Alfa Aesar.
Protocol for the APTT Assay
(a) Collection of Blood Samples—Blood samples were obtained from healthy donors
with approval from Institutional Review Board (protocol 12502A) by the Department of
Radiology at the University of Chicago Hospitals. Whole blood was collected in Vacutainer
tubes at a ratio of 1 part 3.2% sodium citrate to 9 parts blood to obtain decalcified whole blood.
Tubes were gently shaken to mix the contents. For experiments using donor’s whole blood
(which contains both cells and plasma), samples were used from the Vacutainer tubes without
further processing. For experiments using donor’s platelet-rich plasma (PRP), plasma was
obtained after the samples from Vacutainer tubes were centrifuged twice at 1600 rpm for 10
min.91 Normal pooled plasma (platelet-poor plasma, PPP) was obtained from George King
Biomedical (Overland Park, KS) and stored at −80 °C. These pooled plasma samples were
composed of plasma from at least 30 healthy donors. For experiments using normal pooled
plasma (PPP), samples were defrosted and then centrifuged at 1500 rcf for 15 min to remove
the deposited debris resulted from prolonged storage.
(b) Typical Procedure for Measuring the APTT—The reaction network of blood
coagulation is composed of ~80 biochemical reactions among many proteins, including those
called clotting factors.1 These reactions are generally categorized into two pathways: the
intrinsic pathway and the extrinsic pathway. The APTT assay measures the time required for
clotting when initiated by the intrinsic pathway. APTT reagents contain two components: (i)
negatively charged particles that bind factor XII to initiate the intrinsic pathway and (ii)
phospholipids to provide binding sites required for factor complexes. For Alexin, the APTT
reagent used in this work, the activator was ellagic acid and the phospholipid was rabbit brain
cephalin. First, one part of decalcified blood samples is mixed with one part of Alexin and the
resultant mixture is incubated for 3 min to sufficiently activate the intrinsic pathway of
coagulation. This mixture of plasma and Alexin is then recalcifed with one part of 20–25 mM
CaCl2.4 The final concentration of CaCl2 is ~7–8 mM. Excess CaCl2 is used to overcome the
effect of citrate. Finally, the time that elapses between the addition of CaCl2 and the detection
of fibrin clots within the sample is recorded as the APTT. This procedure was used as a
guideline for adapting the plug-based microfluidic device to measure the APTT.
Clinical results for the APTTs were measured with the STA Coagulation Analyzer (Diagnostica
Stago, Inc., Parsippany, NJ) by the Coagulation laboratory at the University of Chicago
Hospital.
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Microfluidic Setup
(a) Fabrication of Devices—Microfluidic devices were fabricated using rapid prototyping
in poly(dimethylsiloxane) (PDMS).9,92,93 Microchannels were rendered hydrophobic and
fluorophilic using the silanization protocol described previously51 with the exception that
tridecafluoro-1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane vapor flowed into the device for 1.5 h
rather than 1 h. In addition to the silanization protocol, the microchannels were coated with
amorphous Teflon (Teflon AF 1600, poly[4,5-difluoro-2,2-bis(trifluoromethyl)-1,3-dioxole-
co-tetra-fluoroethylene]).94–96 First, microchannels were filled with a 1% (w/v) Teflon AF
1600 solution in a 1:4 (v/v) mixture of FC-70 and FC-3283. For experiments conducted at 37
°C, microchannels were filled with a 2.5% (w/v) Teflon AF 1600 solution in a 1:1 (v/v) mixture
of FC-70 and FC-3283. Then, devices were baked at 70 °C overnight until the solution
evaporated. Composite glass/PDMS capillary devices were fabricated as described
previously97 with the exception that glass capillaries were rendered hydrophilic using a Plasma
Prep II plasma cleaner before coupling to the PDMS device.
(b) Microfluidic Experiments—Microfluidic experiments were conducted as described
previously51,54,65 with the following modifications. Plugs were formed using a fluorinated
carrier fluid, which was a mixture of 10:1 (v/v) FC-70/PFO, where γ= 10 mN m−1 and μ = 24
mPa s at 23 °C. Harvard Apparatus PHD 2000 infusion pumps were used to drive flows within
devices. Flow rate of the fluorinated carrier fluid was maintained at 3 μL/min. Aqueous
solutions used to form plugs were Alexin and blood samples (which were either whole blood,
platelet-rich plasma, or platelet-poor plasma; more information in the next paragraphs). For
Alexin, the flow rate was 0.3 μL/min for experiments conducted at 23 °C and 1.2 μL/min for
experiments conducted at 37 °C. For the two blood streams, the total flow rate was 0.3 μL/min
for 23 °C and 1.2 μL/min for 37 °C. A droplet of 100 mM CaCl2 solution (300 mOs) was
injected into each plug at the merging junction. The flow rate of the CaCl2 solution was 0.2
μL/min for 23 °C and 0.4 μL/min for 37 °C. Estimated from the flow rate of the Alexin, the
two blood streams and the CaCl2 solution, the concentration of CaCl2 was 25 and 14 mM for
experiments at 23 and 37 °C, respectively. Excess CaCl2 was used to overcome the effect of
citrate. For experiments at 37 °C, a microscopic heating stage (Brook Industries, Lake Villa,
IL) was used to keep the devices at 37 °C.
In all figures (except in Figure 2), the main PDMS channel of the microfluidic device was 300
μm × 270 μm (width × height), and the small channel was 100 μm × 100 μm. In Figure 2a, the
main PDMS channel and the side channel both were 200 μm × 250 μm. In Figure 2b, the main
PDMS channel was 200 μm × 250 μm, and the small side channel was 50 μm × 50 μm. In
Figure 2c, the main PDMS channel was 200 μm × 260 μm, and the height of the sidearm and
the corner volume was 80 μm.
(c) Measurement of the APTT with Whole Blood Samples—For microfluidic
experiments with whole blood, the stock solutions in the aqueous syringes were (i) Alexin, (ii)
whole blood, and (iii) whole blood with 3.0 μg/mL argatroban. Experiments were conducted
using either a Leica DM IRB or DMI6000 microscope. Fibrin clots within plugs formed with
whole blood were detected optically using a Spot Insight color digital camera (Diagnostics
Instruments, Inc).
(d) Measurement of the APTT with Plasma Samples—For microfluidic experiments
with plasma (either platelet-rich or platelet-poor), the stock solutions in the three aqueous
syringes were (i) Alexin, (ii) plasma with 140 μM fluorogenic substrate, prepared by adding
3.5 μL of the stock substrate solution (10 mM in DMSO) into 246.5 μL of plasma, and (iii)
plasma with 140 μM fluorogenic substrate and 3.0 μg/mL argatroban, prepared by adding 3.5
μL of the stock substrate solution and 0.75 μL of agatroban (1 mg/mL) into 245.5 μL of plasma.
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Experiments were conducted using a Leica DMI6000 microscope. Cleavage of the fluorogenic
substrate for α-thrombin was monitored on the microscope by fluorescence, using a DAPI filter
(λex = 350 ± 25 nm, λem = 460 ± 25 nm) and a cooled CCD ORCA ERG 1394 (12-bit, 1344 ×
1024 resolution) (Hamamatsu Photonics, K. K., Hamamatsu City, Japan). Fibrin clots within
plasma samples was monitored on the microscope by bright-field microscopy.
RESULTS AND DISCUSSION
Overall Design of the Microfluidic Chip for Performing the APTT Test
The microfluidic device consisted of five different regions: the plug-forming region, the mixer,
the incubation region, the merging junction, and the detection region (Figure 1). Plugs of the
three aqueous reagents were formed: (i) Alexin, (ii) decalcified blood, and (iii) decalcified
blood mixed with argatroban. The blood sample was either donor’s whole blood, donor’s PRP
or PPP. The flow rate of the Alexin and the combined flow rate of the blood streams were
maintained at a 1:1 ratio, as required by the APTT assay (see Experimental Section for more
information). By varying the relative flow rates of the two blood streams, the concentration of
argatroban within plugs was varied.53,54 Winding channels were incorporated into the design
of the microfluidic network to promote mixing of the reagents within plugs.47,52 The length
of microchannel in the incubation region was specifically designed so that, at the total flow
rate of the aqueous and fluorinated carrier fluid streams, the incubation time of the plugs was
3 min, as specified by the APTT assay (Figure 1, upper region of microchannel network).
The merging junction was required to inject CaCl2 into the plug after incubation (Figure 1,
right side of microchannel network, indicated in blue). More information about this junction
is given below. To accelerate mixing of CaCl2 within the plug, another winding channel was
designed into the microchannel network. The starting time of the APTT (t = 0) was established
when the plugs of blood were merged with the CaCl2 solution at the merging junction. This is
consistent with the one used in clinical laboratories where the starting time of the APTT assay
equals the time of addition of CaCl2 to the blood sample. However, in our preliminary
microfluidic experiments, the clotting time appeared to be dependent on the rate of mixing
(data not shown). The rate of mixing is known to affect a wide range of autocatalytic systems.
98 The effect of mixing on the clotting time will be further investigated using a recently
developed “bumpy” microfluidic mixer, which accelerated chaotic mixing within plugs of
viscous biological samples.49 For more reliable transport of the fibrin clots inside the plugs
without sticking to the PDMS microchannel wall, the surface of the microchannel was first
treated with a fluorinated silane and then coated with amorphous Teflon (see Experimental
Section for more information). To determine the time at which fibrin clots formed within the
plug, images were taken and analyzed by bright-field and fluorescence microscopy in the
detection region (Figure 1, lower region of the microchannel network).
Two New Methods of Merging a Stream into Flowing Plugs
To perform a multistep assay on a plug-based microfluidic system, injection of reagents into
a plug is necessary.45,46,55,99,100 Three merging methods were previously developed for
plug-based microfluidics: (i) the reagent was directly injected into a plug as it moved past the
channel containing the reagent;46 (ii) a small droplet was merged into an adjacent larger plug
in the main channel when the frequency was matched between formation of the droplet and of
the plug;45 (iii) 10 smaller droplets were merged into a single larger plug.55 However, these
three methods were difficult to implement in this assay. At these slow flow rates (0.1–0.2 mm/
s for the CaCl2 stream), contamination of the CaCl2 stream occurred in the side channel when
CaCl2 was directly injected into the passing plug (Figure 2a). If a side junction was used with
a smaller width and height, small droplets of CaCl2 formed and did not merge with the passing
plug at the junction (Figure 2b).
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Here, we implemented two new approaches for merging. For the first approach, the merging
junction was designed so that the fluorinated carrier fluid between the plugs flowed into the
sidearm to break off a droplet of CaCl2 within the corner volume (Figure 2c). To make this
design, the size of the aqueous plug and the carrier fluid spacing between plugs was
characterized for various water fractions, wf (Supporting Information). Using this design, the
frequency was matched between the plug passing that junction and the droplet forming at the
corner volume. Successful merging was dependent on the ratio of UCaCl2/Uaqueous and not on
the water fraction, wf = Uaqueous/Utotal, where UCaCl2 (μ L/min) is the flow rate of the
CaCl2 stream, Uaqueous (μL/min) is the total volumetric flow rates of the aqueous streams for
blood and Alexin, and Utotal (μL/min) is the total volumetric flow rates of the blood, Alexin,
and carrier fluid streams. Data are included in the Supporting Information to show the
dependence of length of plugs and carrier fluid spacing between plugs as a function of wf and
Utotal (μL/min). For wf = 0.4, the highest percentage of successful merging events (95%) was
observed when UCaCl2/Uaqueous = 0.125, where UCaCl2 was maintained at 0.1 μL/min (Figure
2d, solid symbols). If UCaCl2/Uaqueous was maintained at 0.125, then successful merging (92–
99%) was observed for various wf from 0.36 to 0.45 (Figure 2d, open symbols). The advantage
of this approach was that it did not require extensive fabrication effort. However, merging did
not occur consistently over a wide range of UCaCl2/Uaqueous.
The second approach (Figure 3a) relied on control of surface chemistry of the side channel.
We used a small side channel to avoid back-contamination (as in Figure 2b) but made it
hydrophilic. The merging junction was fabricated by inserting a hydrophilic capillary into this
side channel. The solution of CaCl2 remained attached to the capillary due to wetting, and the
undesirable droplets seen in Figure 2b did not form (movie available in Supporting
Information). It is important to (i) insert the capillary flush with the edge of the main channel
for this method to work and (ii) have size of blood plugs larger than size of CaCl2 droplet
(UCaCl2/Uaqueous < 1, typically 0.17–0.33 in experiments here). When these two requirements
were satisfied, consistent merging (100%, >40 experiments in different devices) was observed
at the flow rates of the aqueous streams (0.6–2.4 μL/min) and the CaCl2 stream (0.2–0.4 μL/
min) we used for APTT assay. The volume of CaCl2 being injected into the plug,
Vinjected CaCl2 (nL), linearly increased with the UCaCl2/Uaqueous (Figure 3b). Using this method,
only small volumes of the CaCl2 reagent (2–10 nL) could be injected into the plug (~40 nL
before merging). By controlling the flow rates, the exact amount of the injecting reagent could
be easily controlled. This merging approach was used for direct injection of CaCl2 solution for
APTT measurement for the rest of this paper.
Detecting Clots within Plugs and Analyzing Images To Measure the APTT and Thrombin
Generation
The APTT is the elapsed time from the addition of CaCl2 to the detection of fibrin clots within
the blood sample. In most point-of-care devices and commercially available machines used in
testing centers, formation of the fibrin clot is detected by detecting changes in optical
transmittance or in movement of magnetic particles. In this report, fibrin clots within plugs
were detected by bright-field and thrombin generation within plugs was detected by
fluorescence microscopy. By analyzing images taken of plugs traveling through the
microchannel, we established a standardized method to determine the APTT in plugs.
(a) Detecting Fibrin Clots in Plugs of Donor’s Whole Blood—For plugs formed with
whole blood, bright-field microscopy was used to detect the trapping of red bloods cells (RBCs)
within fibrin clots. The APTT was determined to be the time at which the RBCs within the
plug were no longer moving (relative to the motion of the plug flowing through the
microchannel). Series of images of a single plug were acquired at 2 frames/s (movie available
in Supporting Information). To follow a single plug, the microscope stage was moved at the
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same speed relative to the speed of the plug moving through the microchannel. Before clotting,
the RBCs were evenly distributed and were moved by internal circulation within the plugs.
45,101 After some time, small clumps of RBCs appeared within the plug but other RBCs still
moved by internal circulation (Figure 4a, top image, t = 121 s). The shear (~2 s−1) within
moving plugs was much lower than that required to induce clotting by activating platelets (~750
s−1).102–104 At a later time, a larger and denser clump of RBCs trapped in a fibrin clot moved
to the back half of the plug while the rest of the RBCs did not move due to being trapped within
the fibrin network (Figure 4a, bottom image, t = 136 s). For the plug shown in Figure 4a, the
APTT of the plug was t = 136 s at 23 °C. We define ttrans (s) as the time that elapses from the
first sign of clotting (Figure 4a, top image) to when the RBCs no longer move relative to the
plug (Figure 4a, bottom image). For this plug shown in Figure 4a, ttrans was 15 s.
The APTT was also determined from many plugs statistically. At each time point, images were
acquired for at least 20 plugs. From a set of images at each time point, the number of plugs
that contain fibrin clots was counted. This number was divided by the total number of plugs
to obtain the “percentage of plugs clotted” at each time point (Figure 4b). The APTT was the
time for 50% of plugs of whole blood to be clotted. The APTT was 110 s at 23 °C (Figure 4b),
in agreement with previously measured APTTs of 175 ± 58 s at 23 °C and 104 ± 20 s at 25 °
C.105 The average ttrans was 15.4 ± 2.8 s for nine plugs of whole blood.
(b) Detecting Clots within Plugs Formed with Donor’s Plasma (Platelet-Rich)—
Clinical laboratories frequently measure the APTT using plasma rather than whole blood. We
determined the APTT in plasma with two methods: using bright-field microscopy to observe
formation of dense fibrin clots and using fluorescent microscopy to detect cleavage of a
fluorogenic substrate by thrombin. To observe fibrin clots in plasma using bright-field
microscopy, a time series of images was acquired for a single plug traveling through the
microchannel (Figure 5a, left panels). A digital convolution filter Sobel (from Metamorph
software) was used to aid the visual detection of the clot (Figure 5a, right panels). For the plug
shown in Figure 5a, the APTT was ~113 s and ttrans was 14 s. We define ttrans (s) as the period
of time that elapses from the first sign of clotting (Figure 5a, first image) to when the fibrin
clot no longer moves relative to the plug (Figure 5a, fifth image).
Using fluorescence microscopy, a more quantitative determination of the thrombin generation
can be made for plugs of plasma. We used a fluorogenic substrate for thrombin. When cleaved
by thrombin, the fluorescence intensity of the substrate increases by ~10-fold.90 Thrombin is
the final enzyme produced in the coagulation network, and it drives formation of the fibrin clot
by cleaving fibrinogen. Fibrin clots form at low concentrations of thrombin (2–10 nM) while
the majority of the thrombin (~1 μM) is produced after the clot is fully formed.106,107
Thrombin favors cleaving fibrinogen compared to the substrate.107,108
A single plug of plasma was followed as it traveled through the microchannel, and the
fluorescence intensity was measured as a function of time (as shown for four plugs, each plug
represented by one black dashed line, Figure 5b). Although the actual APTT of each individual
plugs was different, the time taken for the relative fluorescence intensity to increase from 0 to
1 was the same. To determine the average APTT for many plugs, we correlated the detection
of fibrin clots by bright-field microscopy to the detection of thrombin generation by
fluorescence microscopy. Images were acquired at each time point by bright-field and
fluorescence microscopy from the same experiment. Bright-field images were analyzed to
determine the percentage of plugs clotted as a function of time. The APTT (~100 s) was
determined to be the time at which 50% of the plugs contained fibrin clot (Figure 5b, red
squares). This APTT correlated to a fluorescence intensity of ~30% of the maximum
fluorescence signal (Figure 5b, blue circles).
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Titration of Argatroban and Measurement of the APTT and Thrombin Generation
To determine the effect of the anticoagulant on the APTT, APTTs were measured while
argatroban was titrated into samples of normal pooled plasma, donor’s plasma, or donor’s
whole blood. Measuring the APTT of normal pooled plasma is a standard calibration procedure
for coagulation instruments in central clinical laboratories. Therefore, we also obtained APTTs
from normal pooled plasma. For on-chip titration, one of the two inlet streams of blood
contained 3 μg/mL argatroban. By varying the relative flow rates of these two blood streams,
the concentration of argatroban within the plugs was varied.53,54 Experiments were conducted
at 23 and 37 °C.
For experiments conducted at 23 °C, the effect of argatroban on thrombin generation for the
donor’s plasma samples agreed satisfactorily with the results from the normal pooled plasma
(Figure 6a,b). The APTT ratio is the ratio of the APTT with argatroban in plasma to the baseline
APTT without argatroban. For the donor’s whole blood samples, the APTT ratio at 23 °C
showed a dependence on the concentration of argatroban (Figure 6d). Generally, doses of
argatroban between 0.2 and 2.0 μg/mL are required to achieve an APTT ratio between 1.5 and
3.0. Using this on-chip APTT assay, an APTT ratio of 2.3 was reached for an argatroban dose
of 0.5 μg/mL and an APTT ratio of 2.8 for an argatroban dose of 1.0 μg/mL at 23 °C (Figure
6d). For this donor, a nonlinear dependence of the APTT ratios on the concentration of
argatroban was observed. This dependence was reproducible from experiments with plasma
to experiments with whole blood (Figure 6b,c).
Two modifications from the protocol were required to conduct experiments at the physiological
temperature of 37 °C. First, a more concentrated Teflon AF solution (2.5% w/v instead of 1%
w/v for 23 °C measurements) was used to coat the microchannel to prevent the sticking of
fibrin clots onto the microchannel walls. Fibrin clots were more likely to attach to the walls of
the channel at higher temperatures. Second, a higher injection flow rate of the Alexin and blood
sample was used to form larger plugs (the width-to-length ratio of the plug was ~1:3). While
titrating arga-troban in the same manner as the 23 °C experiments, APTTs were measured for
normal pooled plasma (Figure 7a) and donor plasma (Figure 7b) at 37 °C. APTTs obtained at
37 °C were also ~2.5 times shorter than those at 23 °C. APTT ratios were similar at these two
temperatures. Argatroban of 0.5 μg/mL resulted in an APTT ratio of 2.3 at 23 °C (Figure 6d)
and an APTT ratio of ~2.1 at 37 °C (Figure 7d). Argatroban of 1.0 μg/mL resulted in an APTT
ratio of 2.8 at 23 °C (Figure 6d) and an APTT ratio of 2.7 at 37 °C (Figure 7d). APTT values
and APTT ratios measured by the on-chip assay at 37 °C were compared to results from a
clinical laboratory at 37 °C. Pooled plasma samples were mixed with argatroban (0–1.5 μg/
mL) and submitted to the Coagulation laboratory at the University of Chicago Hospital for
APTT measurements. APTTs obtained from the Coagulation laboratory were consistently
about half of what we obtained from the on-chip assay (Figure 7c). However, the corresponding
APTT ratios from these two methods agreed closely with each other (Figure 7d).
CONCLUSION
Two key technical developments enabled the work presented in this paper. First, the use of a
Teflon AF coating helped minimize sticking of fibrin clots on the walls of microchannels.
Second, reliable addition of a reagent from an aqueous stream into plugs was achieved by
injecting the reagent stream through a hydrophilic narrow glass capillary. This merging method
would be important for performing multistep assays and reactions in plugs, especially when
cross-contamination must be minimized and ratios of reagents must be varied. Whereas bright-
field measurements were a more qualitative metric, fluorescence measurements were used for
quantitative analysis of thrombin generation within plugs. Rather than using a fluorescence
microscope, the detection of fibrin clots within plugs can be simplified by using an array of
LEDs,32 and this detection method would be compatible with plug-based microfluidics. The
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methods developed in this paper would be useful for other assays using blood, including the
prothrombin time assay, the dose determination of heparin and other anticoagulant drugs in
blood samples, and the detection of other analytes within the blood samples. Heparin is a widely
used anticoagulant, and dose determination of heparin is frequently determined by point-of-
care devices, which is especially essential during cardiac surgery.32 Using segmented flow of
air and liquid, flow injection analysis was used to determine the levels of eight analytes within
a sample of blood.42 These results were obtained and forwarded to the physician within 30
min. Rapidly performing multiple tests and dose determinations on a single blood sample using
preloaded reagent cartridges109 is an exciting opportunity that can be realized with this plug-
based microfluidic system. In this paper, measurement of the APTT was simplified by using
a computer-controlled stage to move the field of view over the microfluidic channel and using
a program to automate the acquisition of images at each stage position.
Many types of single-use multichannel devices are already commercially available. These
systems are easy to use as all the components necessary for mixing, addition of reagents, and
detection of the fibrin clot are fully integrated into a single machine. These systems have had
an important impact in critical surgery procedures where a rapid determination of the clotting
time is necessary. One system has used multichannel devices to perform titration experiments
to measure the heparin levels in blood and to measure the platelet-activated clotting test.32 To
measure heparin levels, several channels in a single device contained varying levels of
protamine, where protamine neutralized the anticoagulant properties of heparin. To measure
the platelet-activated clotting test, each channel in the device contained increasing
concentrations of platelet-activating factor. Using this system, each channel required ~800 μL
of blood and so several milliters of blood are needed to perform these titration assays. Using
plug-based microfluidics, each plug contained ~40 nL of the blood sample. To determine the
clotting time at each concentration of argatroban, the clotting time was measured for at least
140 plugs, where each plug can be considered to be an independent experiment. Analysis of
the data was simplified by using an optical microscope with an automated stage. To obtain the
APTT for four concentrations of argatroban, less than 24 μL of blood sample was needed. By
using a preformed cartridge109 containing various clotting agents and reagents, many different
types of assays can be performed with a small amount of blood sample. This feature is
particularly useful for blood samples that are only available in small quantities, such as samples
from children and infants110,111 or small model organisms.112–115
To establish the medical value of this rapid microfluidic titration assay, a clinical study would
be required. Ideally, for each patient, one would use the microfluidic system to predict the
correct dose of an anticoagulant drug, administer the drug, and then validate the prediction by
retesting the clotting properties of the blood sample. In vitro, these microfluidic measurements
do not take into account the pharmacokinetics of the drug. For example, these measurements
would not be valid for the drug warfarin, which works by decreasing the production of clotting
factors in the liver. In the case of argatroban, elimination of the drug varies from patient to
patient further complicating matters. A procedure remains to be established for correlating the
results of microfluidic titrations to the predicted dose for a patient. Such a study is outside the
scope of this paper, which focused on developing microfluidic techniques and on
characterization of this plug-based assay. Now that the microfluidic system is developed and
validated, such a clinical study would be ethically more acceptable and more informative. The
APTT ratios from the two methods (clinical lab versus the on-chip assay) agreed well with
each other. However, the difference in the actual APTT values from these two methods was
interesting. Variations are common among commercial coagulation instruments, where
potential reasons include the differences in sample volume and sample manipulation and in
material composition of the measuring devices.116 Using plug-based microfluidic devices
provides opportunities to understand and explain these differences, by controlling the sample
volume and the interfacial interaction between the blood sample and the wall of the devices.
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Preliminary results (data not shown) indicated that slower initiation of clotting inside plugs
may be due to more efficient mixing in plugs,47 where mixing effects are commonly observed
in autocatalytic systems;98 smaller volume of plugs, where volume effects have been observed
in nonlinear systems;117 and a cleaner interface51 between the plug and the surrounding
fluorinated carrier fluid. A more detailed investigation of these effects will be important for
understanding of the effects of miniaturization on clotting tests. We are especially interested
in using these effects and methods to understand the complex reaction network of blood
clotting.118
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Figure 1.
Schematic of a plug-based microfluidic device for determining the APTT and for titrating
argatroban. Plugs containing Alexin (the APTT reagent) and blood (either plasma or whole
blood) were formed in the plug-forming region, which were then transported to the incubation
region (microphotograph, upper left). After flowing for 3 min, CaCl2 solution was injected
into each plug at the merging junction (microphotograph, upper right). The CaCl2 droplet was
traced with a dashed line in the microphotograph. In the detection region, clots formed within
plugs were observed as a function of time (microphotograph, lower right).
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Figure 2.
Merging within a microfluidic device using a hydrophobic side channel. (a) When the side
channel was hydrophobic (silanized PDMS), contamination occurred (for 5 out of 5
experiments) when the side channel was large (width of 200 μm and height of 250 μm). (b)
However, merging did not occur (for 4 out of 4 experiments) when the side channel was too
small (width and height of 20 μm). Another approach for merging was to form droplets of
CaCl2 at the same frequency as the passing plug. (c) At the junction, the carrier fluid between
the passing plugs flows into the sidearm to break off a droplet from the CaCl2 stream. (d)
Consistent merging was obtained for UCaCl2/Uaqueous = 0.125 at various water fractions wf
(▵). At a constant wf = 0.4, high percentage of merging (95%) was measured only for
UCaCl2/Uaqueous = 0.125 (▪). Each symbol represents measurements from 100 plugs. See text
for definitions and details. All scale bars are for 100 μm.
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Figure 3.
(a) Consistent merging with a hydrophilic glass capillary inserted into the side channel. (b)
The injection volume of CaCl2, Vinjected CaCl2 (nL), into the plug was controlled by flow rate
(μL/min), where UCaCl2 was the flow rate of the CaCl2 stream and Uaqueous was the total
aqueous flow rate for streams of Alexin and blood. In the graph, each symbol represents
measurements for 10 plugs. At least two symbols are shown for each value of UCaCl2/
Uaqueous, where some symbols coincide.
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Figure 4.
Using bright-field microscopy to observe clots within plugs of whole blood. (a) A single plug
of whole blood was followed as it traveled through the microchannel. Time t (s) was time for
the plug traveled after merging with CaCl2. Whole blood within the plug was considered fully
clotted when red blood cells were no longer moving inside the plug and a dense clot was
observed within the back half of the plug (a, bottom image). (b) By analyzing images of plugs
(as in a), the percentage of plugs that contained fibrin clots was determined for each time point
in the detection region. A total of at least 20 plugs were used for each time point. Experiments
were performed at 23 °C.
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Figure 5.
Using bright-field and fluorescence microscopy to observe the formation of fibrin clots within
plugs of PRP. (a) A single plug of plasma was followed as it traveled through the microchannel
(a, left panels). Bright-field images were processed with a digital Sobel filter to see clots more
easily (a, right panels). Plasma was considered fully clotted when the fibrin clot condensed
into the back half of the plug and sequential images of the plug looked the same (compare
image at t = 112.5 s to image at t = 115.5 s). (b) Plugs were formed containing a fluorogenic
substrate for thrombin in plasma. The fluorescence intensity of the substrate increases. In the
graph, each black dashed line represents the fluorescence intensity arisen from an individual
plug, where a single plug was followed as it traveled through the microchannel (total of 4 plugs
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are shown). (•) Integrated intensities obtained from images collected with fluorescence
microscopy were compared to (▪) the percentage of plugs clotted observed from images with
bright-field microscopy. About 50% of the plugs were clotted when the fluorescence intensity
was ~30% of the maximum fluorescence signal. Each symbol represents the measurement of
at least 10 plugs at each time point in the detection region. Experiments were performed at 23
°C.
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Figure 6.
Measurement of thrombin generation and APTT at 23 °C while titrating argatroban into blood
samples. (a, b) Detection of thrombin generation in plasma, (c) measurement of APTT in whole
blood, and (d) the resulting APTT ratios for (c). The concentration of argatroban within the
plugs was (▪) 0, (•) 0.5, (▴) 0.75, and (▾) 1.0 μg/mL. Each symbol represents the measurement
of at least 20 plugs. (c) For whole blood samples, the APTT was the time at which the percentage
of plugs clotted was 50%. (d) The APTT ratio was determined for the whole blood samples at
each concentration of argatroban. The APTT ratio was the ratio of the APTT with argatroban
to the baseline APTT without argatroban.
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Figure 7.
APTT measurements at 37 °C while titrating argatroban into (a) normal pooled plasma, and
(b) donor plasma and corresponding values of the (c) APTT and (d) APTT ratios. For both
plasma samples, the APTT was the time at which 50% of plugs contained fibrin clot. The
concentration of argatroban within the plugs was (▪) 0, (•) 0.25, (▴) 0.5, and (▾) 1.5 μg/mL.
Each symbol represents the measurement of at least 20 plugs. (c) The values of the (⋄) clinical
APTTs with normal pooled plasma were ~2 times lower than the APTTs measured with the
plug-based microfluidic experiments with (▪) normal pooled plasma and (•) donor’s plasma.
(d) The APTT ratios agreed well among the (⋄) clinical APTTs with normal pooled plasma and
the plug-based microfluidic experiments with (▪) normal pooled plasma and (•) donor’s plasma.
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